DLD Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

DLD Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68M	Buy	+40,000	New	+$1.27M	0.11%	114

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

DLD Asset Management's ARKG Position: Q4 2025 in Review

DLD Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2025, closing a stake of 54,327 shares — an estimated $1.51M sold.

DLD Asset Management first reported a position in ARKG in Q3 2025 and held it in 1 quarter. The position peaked at $1.51M in Q3 2025. 239 funds tracked by Wall St. Rank hold ARKG as of Q4 2025.

DLD Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2025 after selling out during the quarter.
DLD Asset Management sold 54,327 ARK Genomic Revolution ETF shares in Q4 2025, an estimated $1.51M.
DLD Asset Management first reported a position in ARK Genomic Revolution ETF in Q3 2025 and held it in 1 quarter.
DLD Asset Management's ARK Genomic Revolution ETF position peaked at $1.51M in Q3 2025.
239 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2025.

Based on DLD Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.